Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 12/20 | 0.32 |
| ▸ | CDK2 | P24941 | 12/20 | 0.32 |
| ▸ | KDR | P35968 | 12/20 | 0.32 |
| ▸ | ATF1 | P18846 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18493721 | 0.86 | STK17B (0.51) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL2724806 | 0.86 | STK17B (0.51) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL2724800 | 0.86 | STK17B (0.51) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL16058267 | 0.84 | MEN1 (0.38) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL13649026 | 0.82 | MEN1 (0.41) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL13649025 | 0.82 | MEN1 (0.41) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL16057613 | 0.80 | MEN1 (0.36) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL21967064 | 0.80 | MEN1 (0.36) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL29474433 | 0.80 | MEN1 (0.36) | MEN1KMT2ASTK17BSTK17AABL1 | |
| SCHEMBL16057611 | 0.80 | MEN1 (0.36) | MEN1KMT2ASTK17BSTK17AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | MEN1 3666/4885KMT2A 513/4885STK17B 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.